AMD assessment and Valeda LDS Treatment
Age-related macular degeneration, or AMD, is an ocular disease characterized by cellular dysfunction in the macula resulting in significant visual impairment. Initially, the sharp, central vision is impacted but the progression of the disease can lead to complete blindness. While there are two forms of the disease, AMD starts with the dry form characterized by protein deposits called drusen that form on the retina (beneath the macula) causing degeneration of the cells over time.
Approximately, 90% of patients with AMD have the dry form and 10% have the wet form.
AMD and the Importance of Eye Exams
The earlier AMD is diagnosed and monitored by an eye care professional, the better the results will be in treating the disease. An eyecare professional can determine how frequently patients need to be seen for check-ups and treatments based on each patient’s unique vision health and family history.
John Rose Is the Worlds first optometrist to offer the NEW approved treatment - Valeda Light Delivery System using PBM to treat DRY AMD.
Treatment is now available only @johnroseeyecare
Age Related Macular Degeneration - What is it? How can it be treated?
What are the new treatments for Age Related Macular Degeneration?
“GLOBALLY AGE-RELATED MACULAR DEGENERATION IS THE PRIMARY CAUSE OF BLINDNESS IN INDUSTRIALISED COUNTRIES.” – World Health Organisation (WHO)
JOHN ROSE IS THE WORLD’S FIRST OPTOMETRIST TO OFFER A NEW TREATMENT FOR AGE-RELATED MACULAR DEGENERATION
What is AMD?
“Age-related macular degeneration (AMD) is a condition generally affecting people over 50 and involves the loss of the person's central field of vision. It occurs when the macular (or central) retina develops degenerative lesions. It is thought that circulatory insufficiency, with reduction in the blood flow to the macular area, also plays a part. Several forms of Age Related Macular Degeneration AMD exist.” -WHO
It is a condition where the back of the eye (the retina) deteriorates. AMD is highlighted by the presence of compounds called “drusen” which are yellow deposits of fatty proteins. Drusen are mainly present in the layers under the retina but can also occur in the optic nerve.
There are two types of AMD; Dry, and the more acute type – wet (or neovascular). Both of which lead to symptoms such as blurring vision, light sensitivity, poor night vision and central vision loss. The difference being that Wet AMD includes the presence of leaking vessels into the vitreous (fluid) of the eye with more severe atrophy. Usually, Dry AMD is only diagnosed in early stages due to regular eye health examinations as symptoms don’t appear until AMD has progressed and retinal integrity has significantly declined. Statistically, only 10-15% of those with Dry AMD will progress to Wet AMD.
AMD is not just caused by natural ageing; influential factors include genetic inheritance and race, even the degree of iris pigmentation, with lighter coloured eyes being at higher risk. More recent studies have shown that environmental and lifestyle factors can affect the likelihood of developing AMD. Ultraviolet Rays, high levels of exposure to vehicular pollution, smoking, abnormally high cholesterol levels and arterial hypertension are also thought to influence AMD development.
To date, treatment options for Dry AMD have been limited to dietary supplements and lifestyle interventions. However, the new and only approved treatment for Dry Macular Degeneration is here, using a safe, non-invasive and painless therapy - photobiomodulation. The Valeda Light Delivery System (Valeda LDS), developed by LumiThera, provides a direct new treatment for Dry Age – Related Macular Degeneration.
How it works?
Photobiomodulation therapy, or cold laser therapy as it has been known previously utilises wavelengths of red, yellow and near infra-red light to rejuvenate on a cellular level. Within our cells are mitochondria which are found by the thousands, these organelles are responsible for producing the chemical energy component ATP, which our body uses in every process.
These wavelengths of light remove a limiting factor in the production of this chemical energy, increasing the amount of ATP in our body temporarily, giving a boost to these processes. Furthermore, mitochondria are thought to activate cellular cascades and pathways associated with anti-inflammation, pain dilution and fortify neurology.
Currently, the Valeda LDS is the only equipment approved for the treatment of Dry Age Related Macular Degeneration to specifically target the retina and slow down the progression of AMD. Given that the retina is one of the most energy-hungry parts of our body and is subsequently packed with mitochondria, with promising results from the clinical studies to date, and the two clinical studies ongoing in the UK alone.
Having tracked the progress of this therapy and equipment (Valeda LDS) for over 15 years at John Rose Eye Care; we have established unique a protocol within our diagnostic suite using equipment from Cambridge Research Systems, so that we can monitor and track progress, providing quantitative data to support the Valeda LDS treatment. Furthermore, this new treatment is non-invasive, easy, and completely safe (approved by NIH/NICE) without any pharmaceutical engagement or surgery.
YOU CAN NOW BOOK THIS NEW TREATMENT for Dry Age Related Macular Degeneration in Kingston Upon Thames ONLINE INLCUDING AN INITIAL AMD Treatment Suitability Assessment at https://johnroseeyecare.mysight.uk/Patient/Appointment , EMAIL US AT INFO@JOHNROSEEYECARE.CO.UK or call 02085469292.